Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
grade C 57.47 2.52% 1.41
CCXI closed up 2.52 percent on Friday, December 4, 2020, on 67 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical CCXI trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
20 DMA Resistance Bearish 2.52%
50 DMA Support Bullish 2.52%
NR7 Range Contraction 2.52%
NR7-2 Range Contraction 2.52%
Up 3 Days in a Row Strength 2.52%
50 DMA Support Bullish 2.97%
NR7 Range Contraction 2.97%
Older End-of-Day Signals for CCXI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 15 hours ago
20 DMA Resistance about 19 hours ago
Rose Above Previous Day's High about 20 hours ago
Rose Above 20 DMA about 20 hours ago
Up 2% about 20 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Medicine Biopharmaceutical Cancer Immunology Autoimmune Diseases Monoclonal Antibodies Rheumatoid Arthritis Inflammatory Bowel Disease Atopic Dermatitis Kidney Disease Diabetic Nephropathy Dermatitis Immunosuppressants Biotie Therapies Glioblastoma Multiforme Inflammatory Disorders Janus Kinase Inhibitor Inflammatory Disease

Is CCXI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 65.43
52 Week Low 29.6
Average Volume 541,806
200-Day Moving Average 52.88
50-Day Moving Average 55.67
20-Day Moving Average 57.12
10-Day Moving Average 55.93
Average True Range 2.79
ADX 12.1
+DI 22.72
-DI 16.88
Chandelier Exit (Long, 3 ATRs ) 54.45
Chandelier Exit (Short, 3 ATRs ) 56.97
Upper Bollinger Band 60.61
Lower Bollinger Band 53.63
Percent B (%b) 0.55
BandWidth 12.22
MACD Line 0.29
MACD Signal Line 0.41
MACD Histogram -0.116
Fundamentals Value
Market Cap 3.98 Billion
Num Shares 69.2 Million
EPS -0.92
Price-to-Earnings (P/E) Ratio -62.26
Price-to-Sales 50.29
Price-to-Book 9.54
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 60.22
Resistance 3 (R3) 60.03 58.93 59.76
Resistance 2 (R2) 58.93 58.23 59.02 59.60
Resistance 1 (R1) 58.20 57.80 58.57 58.39 59.45
Pivot Point 57.10 57.10 57.28 57.19 57.10
Support 1 (S1) 56.37 56.40 56.74 56.56 55.49
Support 2 (S2) 55.27 55.97 55.36 55.34
Support 3 (S3) 54.54 55.27 55.18
Support 4 (S4) 54.73